ProQR Therapeutics BV (PRQR) - Total Assets
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) holds total assets worth $124.35 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PRQR net asset value for net asset value and shareholders' equity analysis.
ProQR Therapeutics BV - Total Assets Trend (2012–2024)
This chart illustrates how ProQR Therapeutics BV's total assets have evolved over time, based on quarterly financial data.
ProQR Therapeutics BV - Asset Composition Analysis
Current Asset Composition (December 2024)
ProQR Therapeutics BV's total assets of $124.35 Million consist of 91.6% current assets and 8.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.0% |
| Accounts Receivable | $2.03 Million | 1.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how ProQR Therapeutics BV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ProQR Therapeutics BV stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProQR Therapeutics BV's current assets represent 91.6% of total assets in 2024, an increase from 88.5% in 2012.
- Cash Position: Cash and equivalents constituted 89.0% of total assets in 2024, up from 73.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 1.2% of total assets.
ProQR Therapeutics BV Competitors by Total Assets
Key competitors of ProQR Therapeutics BV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
ProQR Therapeutics BV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.36 | 2.33 | 7.77 |
| Quick Ratio | 3.36 | 2.33 | 7.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $78.19 Million | $52.77 Million | $85.31 Million |
ProQR Therapeutics BV - Advanced Valuation Insights
This section examines the relationship between ProQR Therapeutics BV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.26 |
| Latest Market Cap to Assets Ratio | 0.92 |
| Asset Growth Rate (YoY) | 10.3% |
| Total Assets | $167.96 Million |
| Market Capitalization | $153.80 Million USD |
Valuation Analysis
Near Book Valuation: The market values ProQR Therapeutics BV's assets close to their book value (0.92x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: ProQR Therapeutics BV's assets grew by 10.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ProQR Therapeutics BV (2012–2024)
The table below shows the annual total assets of ProQR Therapeutics BV from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $167.96 Million | +10.27% |
| 2023-12-31 | $152.31 Million | -11.10% |
| 2022-12-31 | $171.32 Million | -18.25% |
| 2021-12-31 | $209.58 Million | +73.49% |
| 2020-12-31 | $120.80 Million | -8.44% |
| 2019-12-31 | $131.93 Million | +19.69% |
| 2018-12-31 | $110.23 Million | +107.58% |
| 2017-12-31 | $53.10 Million | -18.98% |
| 2016-12-31 | $65.54 Million | -34.53% |
| 2015-12-31 | $100.11 Million | -13.14% |
| 2014-12-31 | $115.25 Million | +2458.77% |
| 2013-12-31 | $4.50 Million | +1232.54% |
| 2012-12-31 | $338.00K | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more